Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Brian Himes on Sep 15th, 2026

Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.1875.

A number of research firms recently commented on LUCD. Weiss Ratings downgraded Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Ascendiant Capital Markets increased their price target on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the stock a “buy” rating in a research report on Monday, June 8th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Finally, BTIG Research restated a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a research note on Monday, August 17th.

Check Out Our Latest Research Report on LUCD

Lucid Diagnostics Price Performance

Shares of NASDAQ:LUCD opened at $0.78 on Tuesday. The company has a market capitalization of $159.06 million, a P/E ratio of -1.67 and a beta of 1.10. Lucid Diagnostics has a 1 year low of $0.77 and a 1 year high of $1.63. The business’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.08.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $1.47 million during the quarter, compared to analyst estimates of $1.43 million. On average, sell-side analysts anticipate that Lucid Diagnostics will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. acquired a new position in Lucid Diagnostics during the second quarter worth about $9,477,000. BlackRock Inc. acquired a new stake in shares of Lucid Diagnostics in the 2nd quarter valued at approximately $8,959,000. Two Seas Capital LP bought a new stake in shares of Lucid Diagnostics during the 2nd quarter valued at approximately $6,420,000. Sunbelt Securities Inc. grew its holdings in shares of Lucid Diagnostics by 134.4% during the 1st quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company’s stock valued at $1,035,000 after purchasing an additional 516,014 shares during the last quarter. Finally, XML Financial LLC increased its position in Lucid Diagnostics by 44.8% during the 2nd quarter. XML Financial LLC now owns 323,195 shares of the company’s stock worth $346,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.